SV

Street Verdict

Analyst Scorecard

A record of what Choice Institutional Equities Analysis said publicly, with the source. Not advice.

“Maintained a 'Buy' rating on Sun Pharmaceutical Industries with an unchanged target price of ₹2,300, implying a potential upside of 29.9% from the October 31 closing price. The company is well-positioned for sustained healthy growth, driven by its leadership in the Indian pharmaceutical market, a strong product launch pipeline, and expansion in specialty and innovative medicines, despite near-term US business pressure.”

Choice Institutional Equities Analysis’s track record (trackable calls only): 77 graded calls · 95% CI 35–57%

Sun Pharmaceutical IndustriesBullishCalled 01 Nov 2026
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹2,300, as stated.

Window: 12 months, the default when no time frame is stated.

Window still open: no verdict until a close reaches a level or the window ends.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Sun Pharmaceutical Industries since this call

1-year tracking window
Read the original articleSee Choice Institutional Equities Analysis’s full track record